• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 25, 2016

View Archived Issues

Forty Seven lands $75M series A round

Forty Seven Inc., a young company moving a humanized IgG4 kappa anti-CD47 monoclonal antibody (MAb) through dual phase I studies, completed the first half of a committed $75 million series A financing led by Lightspeed Venture Partners and Sutter Hill Ventures. Clarus Ventures and GV (formerly Google Ventures) also participated in the financing. Read More

OSE, Effimune combine immunotherapy efforts in $34M stock deal

DUBLIN – French immunotherapy firms Orphan Synergy Europe (OSE) Pharma SA and Effimune SAS are pooling their resources in a stock-based transaction, with the aim of creating scale in a rapidly moving field. The deal values Nantes-based Effimune at €30.4 million (US$33.5 million), based on OSE's closing share price (PARIS:OSE) of €7.60 Wednesday. The combined company will be called OSE Immunotherapeutics SA. Read More

Gut-route shell out: Rani raises $50M-plus for oral forms of injectable drugs

Impressively partnered Rani Therapeutics Inc.'s latest round of "more than $50 million" brings to greater than $70 million the amount of cash raised thus far by the firm, which "could be in the clinic in the second half of next year with a molecule that we might develop on our own," CEO Mir Imran told BioWorld Today. Read More

Better biomarkers needed to assess OA therapies, but patient voice still missing

ATLANTA – "It takes a village" to develop biomarkers in osteoarthritis (OA), Chris Leptak, medical officer in the FDA Office of New Drugs, Guidance and Policy Team told participants at the Accelerating Osteoarthritis Clinical Trials Workshop co-sponsored by the Arthritis Foundation and the FDA. Read More

Industry turns to South Korean officials to boost biopharma

HONG KONG – South Korean biopharma companies are urging the government to speed up the implementation of supporting policies, particularly tax policies that could make it easier for young bioventures to become competitive. Read More

Financings

Polypid Ltd., of Petah Tikva, Israel, closed a $22 million private equity financing. The financing was co-led by new investor Shavit Capital and current investor Aurum Ventures. Read More

Earnings

Jazz Pharmaceuticals plc, of Dublin, reported adjusted net income for 2015 of $600 million, or $9.52 per diluted share, compared to $520.5 million, or $8.31 per diluted share, for 2014. Read More

Other news to note

Antibe Therapeutics Inc., of Toronto, said an article published in PLOS ONE described the ability of anti-inflammatory drug ATB-346 to prevent and reverse tumorigenesis in mice that carry the same genetic mutation, called APCmin, which is found in more than 80 percent of humans with colon cancer. Read More

Appointments and advancements

Recro Pharma Inc., of Malvern, Pa., appointed Fred Graff chief commercial officer. Read More

In the clinic

Biotime Inc., of Alameda, Calif., said subsidiary Asterias Biotherapeutics Inc. completed an end-of-phase II meeting with the FDA for AST-VAC1, its therapy targeting acute myeloid leukemia. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe